Drug intelligence / Profile preview

argifin

Development stage
Unknown
Modality
Peptides, Small Molecules
01

Overview

Argifin is a synthetic oligopeptide and a potent chitinase inhibitor originally isolated from soil microorganisms. It acts as a sub-nanomolar inhibitor of several chitinases including those from Serratia marcescens (SmChiA and SmChiB), Aspergillus fumigatus (chitinase B1), and human chitotriosidase. Argifin has demonstrated IC50 values in the low micromolar to nanomolar range for these targets. Its primary mechanism is competitive inhibition of chitinases by binding to their active sites. Argifin is considered an experimental compound with no current clinical indications or approvals[1][3][7][9].

Other names
243975-37-3(2R,5S,8S,11S,15S)-5-[3-[[amino-(methylcarbamoylamino)methylidene]amino]propyl]-8-benzyl-2,7-dimethyl-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentazacycloheptadecane-11,15-dicarboxylic acid
02

Targets

AfChiB1 (Aspergillus fumigatus chitinase B1)CHIT1 (Chitotriosidase)

Beyond the preview

Go deeper on argifin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on argifin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call